Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

Original Research

(2717) Views  (569) Full article downloads

Authors: Peter J O’Brien, Rajeev Ramanathan, Jonathan M Yingling, Jose Baselga, Mace L Rothenberg, et al

Published Date September 2008 Volume 2008:2(3) Pages 563 - 569

DOI: http://dx.doi.org/10.2147/BTT.S2874

Peter J O’Brien¹, Rajeev Ramanathan², Jonathan M Yingling¹, Jose Baselga³, Mace L Rothenberg⁴, Michael Carducci⁵, Thomas Daly¹, Dorothy Adcock², Michael Lahn¹

¹Eli Lilly and Company Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA; ²Esoterix Coagulation, Aurora, CO, USA; ³Vall d’Hebron University Hospital, Barcelona, Spain; ⁴Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA; ⁵The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA

Abstract: Transforming growth factor beta (TGFβ) plays an important role in cancer, but accurate measurement of circulating TGFβ is complicated by the high TGFβ content of platelets which can release TGFβ ex vivo. We evaluated the use of citrate-theophylline-adenosine-dipyridamole (CTAD) tubes to reduce preanalytical variation in TGFβ measurements caused by ex vivo platelet activation. CTAD substantially reduced ex vivo platelet activation relative to traditional plasma collections in normal donors, which correlated with a decrease in measured TGFβ levels. We show that TGFβ levels are elevated in the majority of cancer patients with skeletal metastases, and that within-patient variability of these levels is relatively low over several weeks. Patients with elevated TGFβ could be subdivided into groups with or without evidence of platelet contribution to measured TGFβ levels. The use of CTAD tubes allows a better determination of a patient’s TGFβ status, and may improve classification of patients with oncologic disease.

Keywords: TGFβ, cancer, biomarker, CTAD

Other articles by Dr Michael Lahn